Phase 3 Clinical Trials With Primary Completion Dates in February 2024
This is a list of Phase 3 trials with primary completion dates in February 2024 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ALVO | Alvotech | 2024-02-01 | Phase 3 | NCT05986786 | Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Disease |
| ALVO | Alvotech | 2024-02-01 | Phase 3 | NCT05842213 | Comparative, Multicenter Study in Subjects With Rheumatoid Arthritis, ALVOFLEX |
| CASBF | CanSino Biologics Inc. | 2024-02-01 | Phase 3 | NCT05951725 | A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP) |
| CRNX | Crinetics Pharmaceuticals, Inc. | 2024-02-01 | Phase 3 | NCT05192382 | A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2) |
| EIGR | Eiger BioPharmaceuticals, Inc. | 2024-02-01 | Phase 3 | NCT04727424 | Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms |
| ITCI | Intra-Cellular Therapies, Inc. | 2024-02-01 | Phase 3 | NCT04985942 | Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder |
| MNKD | MannKind Corporation | 2024-02-01 | Phase 3 | NCT04974528 | Afrezza® INHALE-1 Study in Pediatrics |
| PTGX | Protagonist Therapeutics, Inc. | 2024-02-01 | Phase 3 | NCT05210790 | A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera |
| RARE | Ultragenyx Pharmaceutical Inc. | 2024-02-01 | Phase 3 | NCT05139316 | A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa) |